Metraipolis › archive › dc_903b098563fe
Retrospective analysis of the efficacy and safety of anlotinib plus sintilimab (anti-PD-1) as maintenance therapy in advanced pediatric solid tumors — Europe PMC PMID:41001046
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41001046
- DOI
- 10.3389/fonc.2025.1518987
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T00:56:21.414Z
- SHA-256 of the archived text
84e90f6ac6ca49e387c06658e19b1f7603d90d5920e4cbbc9d7357674b97a3d0- Stable URL of this page
https://metraipolis.com/documento/dc_903b098563fe
How to cite
Retrospective analysis of the efficacy and safety of anlotinib plus sintilimab (anti-PD-1) as maintenance therapy in advanced pediatric solid tumors — Europe PMC PMID:41001046 — Europe PMC (en), https://europepmc.org/article/MED/41001046 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_903b098563fe (Metraipolis archive dc_903b098563fe, sha256 84e90f6ac6ca49e387c06658e19b1f7603d90d5920e4cbbc9d7357674b97a3d0)
BibTeX
@misc{dc903b098563fe,
title = {Retrospective analysis of the efficacy and safety of anlotinib plus sintilimab (anti-PD-1) as maintenance therapy in advanced pediatric solid tumors — Europe PMC PMID:41001046},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41001046},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_903b098563fe; sha256 84e90f6ac6ca49e387c06658e19b1f7603d90d5920e4cbbc9d7357674b97a3d0},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41001046. Agents can read the archived copy with the MCP tool read_document.